Sugi Predict

Sugi Predict / Compounds / SCHEMBL15526484

SCHEMBL15526484

SCHEMBL15526484

OCc1cc(Cl)ncc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.39
▸ PDXK O00764 1/20 0.37
▸ CSNK2A1 P68400 1/20 0.32
▸ PLAU P00749 1/20 0.31
▸ GABRP O00591 1/20 0.31
▸ GABRD O14764 1/20 0.31
▸ GABRA1 P14867 1/20 0.31
▸ GABRB1 P18505 1/20 0.31
▸ GABRG2 P18507 1/20 0.31
▸ GABRB3 P28472 1/20 0.31
▸ GABRA5 P31644 1/20 0.31
▸ GABRA3 P34903 1/20 0.31
▸ GABRA2 P47869 1/20 0.31
▸ GABRB2 P47870 1/20 0.31
▸ GABRA4 P48169 1/20 0.31
▸ GABRE P78334 1/20 0.31
▸ GABRA6 Q16445 1/20 0.31
▸ GABRG1 Q8N1C3 1/20 0.31
▸ GABRG3 Q99928 1/20 0.31
▸ GABRQ Q9UN88 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22574251 0.84 RECQL (0.33) RECQLCSNK2A1
SCHEMBL31092303 0.84 RECQL (0.33) RECQLCSNK2A1
SCHEMBL27238810 0.83 PDXK (0.41) RECQLPDXKCSNK2A1PLAUGABRP
SCHEMBL15871930 0.83 RECQL (0.31) RECQL
SCHEMBL1506399 0.81 — —
SCHEMBL903476 0.80 PDXK (0.45) RECQLPDXKGABRPGABRDGABRA1
SCHEMBL29416192 0.80 PDXK (0.45) RECQLPDXKGABRPGABRDGABRA1
SCHEMBL22677159 0.79 — —
SCHEMBL18083229 0.79 NOS3 (0.34) CSNK2A1GABRPGABRDGABRA1GABRB1
SCHEMBL9013530 0.78 PDXK (0.31) PDXK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4306529-B1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2026-01-21 — — EP disclosed
US-12522605-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
US-12503471-B2 Triazatricycle compounds for the treatment of autoimmune disease HOFFMANN-LA ROCHE INC. (US) 2025-12-23 — — US disclosed
CN-119874707-A FGFR inhibitors and methods of use thereof 传达治疗有限公司 2025-04-25 — — CN disclosed
WO-2025060978-A1 TRICYCLIC PYRIDINE COMPOUND ACTING AS SARM1 ENZYME ACTIVITY INHIBITOR, AND USE THEREOF 科辉智药(深圳)新药研究中心有限公司 2025-03-27 — — WO disclosed
CN-119661547-A Tricyclic pyridine compounds as SARM1 enzyme activity inhibitors and application thereof 科辉智药(深圳)新药研究中心有限公司 2025-03-21 — — CN disclosed
CN-114126620-B FGFR inhibitors and methods of use thereof 传达治疗有限公司 2024-12-31 — — CN disclosed
US-20240158415-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HIBERCELL INC (US) 2024-05-16 — — US disclosed
EP-4335512-A2 CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS HiberCell, Inc. (US) 2024-03-13 — — EP disclosed
EP-4306529-A2 FGFR INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2024-01-17 — — EP disclosed
US-9353101-B2 Cyclic amine substituted heterocyclic CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2016-05-31 — — US disclosed
EP-2968280-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF Genentech, Inc. (US) 2016-01-20 — — EP disclosed
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2016-01-14 — — US disclosed
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2016-01-14 — — US disclosed
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2016-01-14 — — US disclosed
US-20150111866-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-23 — — US disclosed
EP-2844252-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-03-11 — — EP disclosed
WO-2014153037-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2014-09-25 — — WO disclosed
WO-2014153037-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2014-09-25 — — WO disclosed
WO-2013165854-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-11-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111866-A1 CYCLIC AMINE SUBSTITUTED HETEROCYCLIC CETP INHIBITORS CETP, APOB, MTTP RECQL 971/4885PDXK 2439/4885CSNK2A1 1448/4885
US-20240158415-A1 AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS PIP5K1B, PIP5K1A, PIP5K1C RECQL 889/4885PDXK 35/4885CSNK2A1 676/4885
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF P2RX3, P2RX1, P2RX4 RECQL 53/4885PDXK 1396/4885CSNK2A1 706/4885
US-12503471-B2 Triazatricycle compounds for the treatment of autoimmune disease SSB, HLA-DRB1, PKD1 RECQL 760/4885PDXK 1248/4885CSNK2A1 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.